Therapy and prevention of arthritis by recombinant adeno-associated virus vector with delivery of interleukin-1 receptor antagonist

Arthritis and Rheumatism

Volumn 43, Issue 2, 2000, Pages 289-297

  Pan, Ru Yu ^a   Chen, Show Li ^b   Xiao, Xiao ^c   Liu, Dai Wei ^b   Peng, Ho Jeng ^d   Tsao, Yeou Ping ^b,e  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^e CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; LIPOPOLYSACCHARIDE; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; DISEASE SEVERITY; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE TARGETING; GENE THERAPY; LEUKOCYTE COUNT; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR UPREGULATION; RECURRENT DISEASE; SYNOVIAL FLUID LEVEL; TRANSGENE;

ANIMALS; ARTHRITIS, EXPERIMENTAL; DEPENDOVIRUS; GENE THERAPY; GENETIC VECTORS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; SIALOGLYCOPROTEINS; SYNOVIAL FLUID; TRANSGENES; VIRAL PROTEINS;

EID: 0034130299     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(200002)43:2<289::AID-ANR8>3.0.CO;2-H     Document Type: Article

References (38)

1. Kaklamanis PM. Experimental animal models resembling rheumatoid arthritis. Clin Rheumatol 1992;11:41-7.
2. Arend WP, Dayer J-M. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor a in rheumatoid arthritis. Arthritis Rheum 1995;38:151-60.
3. Dayer JM, Fenner H. The role of cytokines and their inhibitors in arthritis. Ballieres Clin Rheumatol 1992;6:485-516.
4. Tyler JA. Articular cartilage cultured with catabolin (pig interleukin 1) synthesizes a decreased number of normal proteoglycan molecules. Biochem J 1985;227:869-78.
5. 2 release from cartilage in organ culture. Arthritis Rheum 1989;32:288-97.
6. Lefebvre V, Peeters-Horis C, Vaes G. Modulation by interleukin-1 and tumor necrosis factor alpha of production of collagenase, tissue inhibitor of metalloproteinases and collagen types in differentiated and dedifferentiated articular chondrocytes. Biochim Biophys Acta 1990;1052:336-78.
7. Kandel RA, Petelycky M, Dinarello CA, Minden M, Pritzker KPH, Cruz TF. Comparison of the effect of interleukin-6 and interleukin-1 on collagenase and proteoglycan production by chondrocytes. J Rheumatol 1990;17:953-7.
8. Wood DD, Ihrie EJ, Dinarello CA, Cohen PL. Isolation of an interleukin-1-like factor from human joint effusions. Arthritis Rheum 1983;26:975-83.
9. Miyasaka N, Sato K, Goto M, Sasano M, Natsuyama M, Inoue K, et al. Augmented interleukin-1 production and HLA-DR expression in the synovium of rheumatoid arthritis patients: possible involvement in joint destruction. Arthritis Rheum 1988;31:480-6.
10. Henderson B, Thompson RC, Hardingham W, Lewthwaite J. Inhibition of interleukin-1 induced synovitis and articular cartilage proteoglycan loss in the rabbit knee by recombinant human interleukin-1-receptor antagonist. Cytokine 1991;3:246-9.
11. Mohler KM, Torranceet DS, Smith CA, Godwin RG, Stremler KE, Widmer MB, et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993;151:1548-61.
12. Smith RJ, Chin JE, Sam LM, Justen JM. Biological effects of an interleukin-1 receptor antagonist protein on interleukin-1-stimulated cartilage erosion and chondrocyte responsiveness. Arthritis Rheum 1991;34:78-83.
13. Hung GL, Galea-Lauri J, Mueller GM, Georgescu HI, Robbins PD, Evans CH, et al. Suppression of intra-articular responses to interleukin-1 by transfer of the interleukin-1 receptor antagonist gene to synovium. Gene Ther 1994;1:64-9.
14. Otani K, Nita I, Macaulay W, Georgescu HI, Robbins PD, Evans CH. Suppression of antigen-induced arthritis in rabbits by ex vivo gene therapy. J Immunol 1996;156:3558-62.
15. Evans CH, Robbins PD. Possible orthopaedic applications of gene therapy. J Bone Joint Surg Am 1995;77:1103-14.
16. Ghivizzani SC, Lechman ER, Kang R, Tio C, Evans CH, Robbins PD, et al. Direct adenovirus-mediated gene transfer of interleukin-1 and tumor necrosis factor a soluble receptors to rabbit knees with experimental arthritis has local and distal anti-arthritic effects. Proc Natl Acad Sci U S A 1998;95:4613-8.
17. Bakker AC, Joosten LAB, Arntz OJ, Helsen MMAA, Bendele AM, van de Loo FAJ, et al. Prevention of murine collagen-induced arthritis in the knee and ipsilateral paw by local expression of human interleukin-1 receptor antagonist protein in the knee. Arthritis Rheum 1997;40:893-900.
18. Le CH, Nicolson AG, Morales A, Sewell KL. Suppression of collagen-induced arthritis through adenovirus-mediated transfer of a modified tumor necrosis factor α receptor gene. Arthritis Rheum 1997;40:1662-9.
19. Nita I, Ghivizzani SC, Galea-Lauri J, Bandara G, Georgescu HI, Robbins PD, et al. Direct gene delivery to synovium: an evaluation of potential vectors in vitro and in vivo. Arthritis Rheum 1996;39: 820-8.
20. Sawchuk SJ, Boivin G, Duwel L, Ball W, Trapnell B, Hirsch R, et al. Anti-T cell receptor monoclonal antibody prolongs transgene expression on following adenovirus-mediated in vivo gene transfer. Hum Gene Ther 1996;7:499-506.
21. Yang Y, Ertl HC, Wilson JM. MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E-deleted recombinant adenovirus. Immunity 1994;1:433-42.
22. Yang Y, Nunes FA, Berencsi K, Furth EE, Gonczol E, Wilson JM. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci U S A 1994;91:4407-11.
23. Xiao X, Li J, Samulski RJ. Efficient long-term transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol 1996;70:8098-108.
24. Xiao X, Li J, McCown TJ, Samulski RJ. Gene transfer by adeno-associated virus vectors into the central nervous system. Exp Neurol 1997;144:113-24.
25. Afione SA, Conrad CK, Kearns WG, Chunduru S, Carter BJ, Flotte TR, et al. In vivo model of adeno-associated virus vector persistence and rescue. J Virol 1996;70:3235-41.
26. Flotte TR, Afione SA, Conrad C, McGrath SA, Guggino WB, Carter BJ, et al. Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector. Proc Natl Acad Sci U S A 1993;90:10613-7.
27. Muzyczka N. Use of adeno-associated virus as a general transduction vector for mammalian cells. Curr Top Microbiol Immunol 1992;158:97-129.
28. Flotte TR, Barraza-Ortiz X, Solow R, Afinoe SA, Carter BJ, Guggino WB. An improved system for packaging recombinant adeno-associated virus vectors capable of in vivo transduction. Gene Ther 1995;2:29-.37.
29. Pan RY, Xiao X, Chen SL, Li J, Lin LC, Tsao YP, et al. Disease-inducible transgene expression from a recombinant adeno-associated virus vector in a rat arthritis model. J Virol 1999;73:3410-7.
30. Carter DB, Deibel MR, Dunn CJ, Tomich CS, Sun FF, McEwan RN, et al. Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein. Nature 1990;344:633-8.
31. Li J, Dressman D, Tsao YP, Sakamoto A, Hoffman EP, Xiao X. rAAV vector-mediated sarcoglycan gene transfer in a hamster model for limb girdle muscular dystrophy. Gene Ther 1999;6:74-82.
32. Xiao X, Li J, Samulski RJ. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 1998;72:2224-32.
33. Chinol M, Vallabhajosula S, Goldsmith SJ, Paganelli G, Palestro CJ. Evaluation of four radiopharmaceuticals for imaging inflammation in a rabbit model of arthritis. Ann Nucl Med 1996;10:287-91.
34. Moerlein SM, Welch MJ. The chemistry of gallium and indium as related to radiopharmaceutical production. Int J Nucl Med Biol 1981;8:277-87.
35. Bandara G, Mueller GM, Galea-Lauri MH, Glorioso JC, Robbins PD, Evans CH, et al. Intra-articular expression of biologically active interleukin-1-receptor-antagonist protein by ex vivo gene transfer. Proc Natl Acad Sci U S A 1993;90:10764-8.
36. Roessler BJ, Allen ED, Wilson JM, Hartman JW, Davidson BL. Adenoviral-mediated gene transfer to rabbit synovium in vivo. J Clin Invest 1993;92:1085-92.
37. Geiger T, Towbin H, Cosenti-Vargas A, Zingel O, Glatt M, Vosbeck K, et al. Neutralization of interleukin-1 beta activity in vivo with a monoclonal antibody alleviates collagen-induced arthritis in DBA/1 mice and prevents the associated acute-phase response. Clin Exp Rheumatol 1993;11:515-22.
38. Joosten LAB, Helsen MMA, van de Loo FAJ, van den Berg WB. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNFα, anti-IL-1α/β, and IL-1Ra. Arthritis Rheum 1996;39:797-809.